It can be also hypothesized that PHF19-targeting could represent a novel therapeutic approach, considering its link to PRC2 and EZH2, and given the anti-MM activity exerted by single and specific PRC2- or EZH2-targeting. Here, EZH2 is linked to Miyoshi myopathy.